Skip to main content
. Author manuscript; available in PMC: 2014 Sep 23.
Published in final edited form as: Autoimmunity. 2010 Aug 9;44(2):137–148. doi: 10.3109/08916934.2010.482116

Figure 1.

Figure 1

AdLeptin protects BBDR rats from pIC+KRV induced diabetes. BBDR rats were treated with AdLeptin, AdBetagal or PBS prior to pIC+KRV treatment as described in Methods. A. Diabetes free survival of treated BBDR rats was followed for 45 days and defined as the time until the first of two elevated blood glucose levels (> 250 mg/dl) on two consecutive days. Data are pooled from two independent experiments; AdLeptin vs. AdBetagal (p=0.0026), AdLeptin vs. PBS (p < 0.005), AdBetagal vs. PBS (p=0.01). Numbers (n) of rats in each group are shown in parentheses. B. Representative pancreas sections from an AdLeptin + pIC+KRV treated rat protected from diabetes on day 45. C. Representative pancreas sections from a diabetic rat treated with PBS + pIC+KRV and maintained on insulin pellets to the end of the observation period on day 45. All sections were stained with H&E and images obtained at 10x magnification.